Clarivate Analytics collaborates with the University of Melbourne to support the ARC Training Centre for Personalized Therapeutics Technologies in advancing Australian biomedical research
MELBOURNE, June 16, 2017 – Clarivate Analytics announced its collaboration with the University of Melbourne, which is leading the ARC Training Centre for Personalized Therapeutics Technologies, a collaboration between University of Melbourne, Monash University, University of Western Australia and 15 partner organizations including Clarivate.
Funded by the prestigious Australian Research Council’s (ARC) Industrial Transformation Training Centres schemes over five years, the Centre is led by Professor Alastair Stewart from the Department of Pharmacology and Therapeutics, University of Melbourne. The Centre aims to create and develop in Australia the skills and technology to generate early benefits from the transformative impacts that cell/organ-on-a chip technology will have on the medical technology and pharmaceutical industries, as well as deliver on the potential of the era of personalized medicine. Guiding therapeutic use by personalized bioassays promises to enable disease to be modelled or diagnosed with increased precision.
Professor Alastair Stewart, head of the Centre and director of the Lung Health Research Centre, Department of Pharmacology and Therapeutics, University of Melbourne, said “We are delighted to be consolidating our partnership with the team at Clarivate Analytics, facilitating access of the trainees to up-to-date, curated Pharma/Biotech/Academic intelligence delivered on platforms that are intuitive to new users. Early career and graduate researchers will be able to probe new drugs and their targets with efficiency and precision through this ARC-centre based collaboration.”
“We are pleased to leverage our intelligence and expertise in the pharmaceutical and drug development industry to help researchers understand the competition and benchmark the commercial value of their research/drug assets generated from university research, and to ultimately address unmet medical and clinical needs,” said Jeroen Prinsen, vice president and head of Australasia and Southeast Asia at Clarivate Analytics. “A key element to our collaboration with the University of Melbourne is to develop the university’s repertoire of expertise when developing investment-ready programs suitable for in-licensing, co-development or acquisition by SMEs or pharmaceutical companies.”
As industry partner of the Centre, Clarivate Analytics will provide significant in-kind support by having its senior life sciences solutions expert conduct an annual masterclass over five years for researchers on topics covering how to identify competitors, achieve clinical milestones, map the intellectual property (IP) landscape of similar clinical targets and assess the value of drug discovery. To help masterclass students gain practical know-how, Clarivate will also provide free access to its flagship pharma intelligence software, Cortellis Competitive Intelligence, for a limited period. Currently, Clarivate conducts commercialization, partnering and regulatory intelligence lectures which form the curriculum in the Masters of Biotechnology Undergraduate program offered by the University of Melbourne.
“At Clarivate Analytics, we have been supporting the ANZ region with our pharmaceutical and intellectual property information and competitive intelligence across a number of innovation entrepreneurship programs,” Prinsen said, “and we believe that the Centre will provide significant advancement to the skills necessary to increase the commercial potential of Australian research.”
Clarivate™ Analytics accelerates the pace of innovation by providing trusted insights and analytics to customers around the world, enabling them to discover, protect and commercialize new ideas faster. Formerly the Intellectual Property and Science business of Thomson Reuters, we own and operate a collection of leading subscription-based businesses focused on scientific and academic research, patent analytics and regulatory standards, pharmaceutical and biotech intelligence, trademark protection, domain brand protection and intellectual property management. Clarivate™ Analytics is now an independent company with over 4,000 employees, operating in more than 100 countries and owns well‐known brands that include Web of Science™, Cortellis™, Derwent™, CompuMark™, MarkMonitor® and Techstreet™, among others. For more information, please visit clarivate.com.